Articles tagged with: Secondary Cancer
Opinion»

It is autumn here now and the brilliant golds, reds, and greens combine together for the showiest nature display of the year! The sunrises are gold against the charcoal sky, and the prairie hares are changing their fur color from tawny to whitish in preparation for winter snowfalls.
Rather than spending time outside enjoying the beautiful autumn weather, I am preoccupied with a new wrinkle in my health that may or may not be related to my multiple myeloma: a secondary cancer. It has been caught early, and I am hopeful that …
News»

Good morning, myeloma world.
After a busy week here at Myeloma Morning Headquarters, we're pleased to report that things are a bit more relaxed today. We're not sure if it's the weekend, or the cooler, overcast weather outside. Whatever the reason, we're enjoying the somewhat slower pace.
That pace is reflected in what we'll be covering in today's edition of Myeloma Morning. We'll be discussing just three new myeloma research articles.
The first article is a discussion of how to treat relapsed multiple myeloma, co-authored by Dr. Pieter Sonneveld, a leading myeloma …
News»

The findings of a recent retrospective study may alleviate some of the concerns patients and physicians have had about Revlimid and the risk of secondary cancers.
The study found that the risk of developing a secondary cancer as a result of treatment with Revlimid occurred mainly when a patient had been treated with oral melphalan at the same time as Revlimid.
Revlimid (lenalidomide) did not appear to be associated with an increased risk of secondary cancers when administered together with dexamethasone or cyclophosphamide.
In addition, although treatment with Revlimid before …
News»

This year’s Congress of the European Hematology Association (EHA) is currently being held in Stockholm. It started earlier this week and will run through Sunday, June 16.
A substantial amount of myeloma-related research will be presented during the EHA meeting during both oral presentations and poster presentations.
This article summarizes some of the important myeloma-related findings that are expected to be presented during poster sessions today and tomorrow. A previous article covered the key findings that will be presented during oral presentations.
The studies covered in this article are primarily ones …
News»

Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year. The first education and poster sessions of the meeting will take place tomorrow, Friday, June 14. Additional sessions of various kinds are scheduled for both days of the weekend, until the meeting ends early Sunday afternoon (European time).
The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related diseases, including multiple myeloma.
The EHA meeting is …
News»

This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago.
Monday was the busiest day with regard to myeloma-related research. The day started with an oral presentation session that included eight talks about important new myeloma-related research. A poster session in the afternoon included several posters about myeloma-related research.
This article summarizes the most important findings from Monday's oral presentation session. A later article will cover the findings from the afternoon poster session.
The content in our daily updates is based on the …
News»

The American Society of Clinical Oncology will hold its 49th annual meeting May 31 through June 4 in Chicago.
Similar to previous years, more than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Building Bridges to Conquer Cancer.”
During the meeting, there will be presentations and seminars about all areas of cancer, including many focused specifically on multiple myeloma. The ASCO website currently lists more than 60 myeloma-based presentations (included …